Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Accelerated rTMS vs. Sham for Stroke Apathy

NCT: NCT07113067 · RECRUITING

NCT IDNCT07113067
StatusRECRUITING
Start Date2025-08-08
Completion2027-06-30
SponsorMedical University of South Carolina (OTHER)
First posted
Last updated

Brief Summary

Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.

Frequently Asked Questions

What is Accelerated rTMS vs. Sham for Stroke Apathy?

Accelerated rTMS vs. Sham for Stroke Apathy is a clinical trial registered under NCT07113067. Current status: RECRUITING.

What is the status of NCT07113067?

The current status of NCT07113067 (Accelerated rTMS vs. Sham for Stroke Apathy) is: RECRUITING.

When did Accelerated rTMS vs. Sham for Stroke Apathy start?

Accelerated rTMS vs. Sham for Stroke Apathy started on 2025-08-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.